EAM Investors’s Kite Pharma, Inc. KITE Stock Holding History

EAM Investors’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-37,995	Closed	-$2.98M	–	413
2017 Q1	$2.98M	Buy	+37,995	New	+$2.35M	0.47%	80
2016 Q2	–	Sell	-57,204	Closed	-$2.63M	–	414
2016 Q1	$2.63M	Buy	57,204 +9,792	+21%	+$474K	0.41%	98
2015 Q4	$2.92M	Buy	+47,412	New	+$3.34M	0.38%	124

Other funds holding KITE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

EAM Investors's KITE Position: Q2 2017 in Review

EAM Investors sold out of Kite Pharma, Inc. (KITE) in Q2 2017, closing a stake of 37,995 shares — an estimated $2.98M sold.

EAM Investors first reported a position in KITE in Q4 2015 and held it in 3 quarters. The position peaked at $2.98M in Q1 2017. 220 funds tracked by Wall St. Rank hold KITE as of Q2 2017.

EAM Investors reported no remaining Kite Pharma, Inc. position as of Q2 2017 after selling out during the quarter.
EAM Investors sold 37,995 Kite Pharma, Inc. shares in Q2 2017, an estimated $2.98M.
EAM Investors first reported a position in Kite Pharma, Inc. in Q4 2015 and held it in 3 quarters.
EAM Investors's Kite Pharma, Inc. position peaked at $2.98M in Q1 2017.
220 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q2 2017.

Based on EAM Investors's 13F filing for Q2 2017, filed 11 Aug 2017.